Completed

Itraconazole Oral Solution vs Fluconazole Tablets for Esophageal Candidiasis in Immunocompromised Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Itraconazole

+ Fluconazole

Drug
Who is being recruted

Blood-Borne Infections+16

+ Urogenital Diseases

+ Genital Diseases

Over 13 Years
+22 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorJanssen Pharmaceuticals
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on comparing two medications, itraconazole oral solution and fluconazole tablets, for the treatment of esophageal candidiasis. Esophageal candidiasis is a condition where a type of fungus called candida infects the esophagus, the tube that connects the throat to the stomach. The study is particularly interested in helping immunocompromised patients, or those with weakened immune systems, as they are more susceptible to this infection. The goal is to find out which medication works better and safer for these patients, potentially improving their care and quality of life.

NCT00002132
Principal SponsorJanssen Pharmaceuticals
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 13 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesBacterial Infections and MycosesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsMycosesRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeCandidiasisHIV Infections

Criteria

4 inclusion criteria required to participate
Esophageal candidiasis.
Life expectancy of at least 2 months.
Histological evidence of Candida spp. at baseline with confirmation by positive mycological culture.
HIV infection or other predisposing risk factor.
18 exclusion criteria prevent from participating
Rifampin.
Judged to be unreliable in regard to following physician's directives.
History of significant hepatic abnormalities or clinical evidence of hepatic disease within 2 months prior to study entry.
H2 blockers.
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 18 locations

Dr Eskild A Petersen

Tucson, United StatesOpen Dr Eskild A Petersen in Google Maps

Los Angeles County - USC Med Ctr

Los Angeles, United States

UCSD Med Ctr

San Diego, United States

George Washington Univ Med Ctr

Washington D.C., United States
Completed18 Study Centers